Parathyroid Hormone Analog Drug Class List

Drugs in Drug Class: Parathyroid Hormone Analog

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Ascendis Pharma Bone	YORVIPATH	palopegteriparatide	SOLUTION;SUBCUTANEOUS	216490-001	Aug 9, 2024		RX	Yes	Yes
Ascendis Pharma Bone	YORVIPATH	palopegteriparatide	SOLUTION;SUBCUTANEOUS	216490-003	Aug 9, 2024		RX	Yes	No
Ascendis Pharma Bone	YORVIPATH	palopegteriparatide	SOLUTION;SUBCUTANEOUS	216490-001	Aug 9, 2024		RX	Yes	Yes			Y
Ascendis Pharma Bone	YORVIPATH	palopegteriparatide	SOLUTION;SUBCUTANEOUS	216490-002	Aug 9, 2024		RX	Yes	No			Y	Y

Market Dynamics and Patent Landscape for Parathyroid Hormone (PTH) Analogs

Last updated: January 5, 2026

Executive Summary

The Parathyroid Hormone (PTH) analog class, primarily used in osteoporosis and hypoparathyroidism treatment, has experienced significant market evolution driven by patent expirations, biosimilar entries, and innovations in drug formulation. The landscape is characterized by a robust pipeline of emerging therapeutics, a complex patent environment prone to legal disputes, and shifting regulatory policies impacting market access. This report provides an in-depth analysis of the current market dynamics, patent protections, and future trajectories for PTH analogs, equipping stakeholders with strategic insights to navigate this complex therapeutic class.

---

What are Parathyroid Hormone (PTH) Analogs?

Definition and Mechanism

PTH analogs mimic the activity of endogenous parathyroid hormone, primarily stimulating bone formation and regulating calcium and phosphate metabolism. They are distinguished by their recombinant protein structure and are classified mainly as:

• Teriparatide (Forteo): The N-terminal 1-34 fragment of PTH, used predominantly for osteoporosis.
• Full-length PTH analogs: Less common but under development for various indications.
• Diverse formulations: Daily subcutaneous injections, long-acting formulations, and biosimilars.

Approved Drugs and Indications

Drug Name	Active Ingredient	Approved Indication	Market Approval Year	Patent Expiry (Approximate)
Forteo (AbbVie)	Teriparatide	Osteoporosis, fracture risk reduction	2002	2027
Tymlos (Cl recognized)	Abaloparatide	Osteoporosis	2017	2033
PTH(1-84) (Fisiogen)	PTH(1-84)	Osteoporosis, hypoparathyroidism	2014	2035

Note: Patent status and commercialization vary based on jurisdiction and patent filings.

---

Market Dynamics of PTH Analogs

What Are the Factors Influencing Market Growth?

1. Clinical Efficacy and Safety Profile

PTH analogs demonstrate significant efficacy in increasing bone mineral density (BMD) and reducing fracture risk. Their safety profile remains acceptable, with risk management protocols in place to minimize osteosarcoma risk (noted in animal studies).

2. Patent Lifecycles and Market Exclusivity

Patent protections are crucial but limited. Forteo’s patent protection expires around 2027, opening doors for biosimilar competition. Patent challenges and extensions, however, influence the timing of generic entries.

3. Biosimilar Entry and Market Competition

With patent expiries looming, biosimilar developers are streamlining approval pathways, especially in Europe (EMA) and the U.S. (FDA), fostering market competition and potentially reducing prices.

Biosimilar Candidate	Developer	Expected Approval	Patent Status	Notes
Biosimilar Forteo	Coherus, Samsung	2025-2027	Pending	Increasing biosimilar activity
Other candidates	Various	2026-2028	Pending	Market entry expected post-patent expiry

4. Regulatory Landscape

Regulators like FDA and EMA have specific pathways for biosimilar approvals, including analytical, preclinical, and clinical comparability data. The recent submission of biosimilar candidates indicates a strategic shift toward cost containment.

5. Pricing and Reimbursement Policies

Pricing flexibility varies by country; payers increasingly favor biosimilars, leading to negotiations that influence drug accessibility. US Medicare and private insurers are adopting formulary strategies favoring lower-cost biosimilars.

6. Clinical Innovation and Pipeline Developments

Next-generation PTH analogs focus on stability, convenience (long-acting formulations), and novel delivery methods (oral, transdermal). Numerous pipeline candidates aim to extend patent protection and improve patient adherence.

---

Market Size and Forecast

Year	Global Market (USD billion)	CAGR (2019-2027)	Main Drivers
2019	1.2	-	Established use, aging population
2023	1.5	5.2%	Increasing osteoporosis prevalence, biosimilar entry anticipation
2027 (forecast)	2.2	8.7%	Patent expiries, pipeline advancements

Source: Industry reports, IQVIA data, 2022 estimates.

---

Patent Landscape Analysis

How Are PTH Analog Patents Structured?

Patent Types

Patent Category	Description	Typical Duration	Notable Features
Composition of Matter	Claims on specific molecules or variants	20 years	Core patent for active molecule
Manufacturing Process	Innovative methods for production	20 years	Can extend exclusivity beyond drug patent
Formulation & Use	Specific formulations or therapeutic applications	20 years	Patent life varies based on claims
Method of Use	Novel indications or administration methods	20 years	Can be strategized for life-cycle extension

Key Patents and their Status

Patent Holder	Patent Type	Filing Year	Expiry Year	Status
Eli Lilly (Forteo)	Composition of matter	1994	2014	Expired (generic/Biosimilar entry in progress)
Eli Lilly	Method of use (osteoporosis)	2001	2021	Expired, biosimilars in development
Other innovator companies	Formulation patents	2010-2018	2030+	Pending or in force

Patent Challenges and Litigation Trends

• Legal disputes have centered on claims of patent infringement by biosimilar developers post-expiry.
• the U.S. Federal Circuit has been pivotal in defining patent life extensions through process and use patents.

International Patent Strategies

• Patent protections are jurisdiction-dependent, with countries like the US, EU, and Japan implementing distinct patent rules.
• Patent applications filed under the Patent Cooperation Treaty (PCT) facilitate global coverage.

---

Comparison of Leading PTH Analogs and Biosimilar Candidates

Attribute	Forteo (AbbVie)	Tymlos (Radius Health)	PTH(1-84) (Fisiogen)	Biosimilar Candidates
Molecular Structure	PTH 1-34	PTH 1-34	PTH 1-84	Similar to Forteo, PTH 1-34 or 1-84
Administration Frequency	Daily	Daily	Daily	Variable (daily, long-acting)
Patent Status	Expiring 2027	Patent protected until 2033	Patent protected until 2035	Pending approval, post-2027
Formulation Innovations	Microdosing, delivery devices	Injectable bioavailability	Injectable, subcutaneous	Long-acting formulations in development

---

What Are the Future Opportunities and Challenges?

Opportunities

• Development of oral PTH analogs: To improve adherence, currently unmet clinical needs exist for non-injectable options.
• Long-acting formulations: Extended dosing intervals can improve patient compliance.
• Expanded indications: Beyond osteoporosis and hypoparathyroidism, potential in fracture healing and other metabolic disorders.
• Manufacturing innovations: Bioprocess improvements can lower production costs and extend patent protections.

Challenges

• Biosimilar competition: Will drive prices down but may impact margins.
• Regulatory hurdles: Biosimilarity demands stringent comparability data, lengthening approval timelines.
• Patent litigations: Complex patent landscape can delay market entry post-expiry.
• Market acceptance: Physicians and patients often prefer established brands, slowing biosimilar adoption.

---

FAQs

1. What is the typical patent life for PTH analog drugs?
   The core composition patents originally last 20 years from filing, but regulatory data exclusivity and secondary patents can extend effective market protection to 25-30 years.

2. How do biosimilars for PTH analogs impact the market?
   Biosimilars lower drug costs, increase accessibility, and threaten brand exclusivity, especially post-patent expiration. Their success depends on regulatory approval, physician acceptance, and payer policies.

3. What are the main regulatory pathways for biosimilar approval?
   Both the FDA and EMA require comprehensive analytical, preclinical, and clinical studies demonstrating biosimilarity in structure, function, and efficacy, with the Biosimilar Pathway being the preferred route.

4. Are there any significant pipeline drugs or formulations of PTH analogs on the horizon?
   Yes. Several long-acting formulations, including weekly injections and transdermal patches, are under development to enhance adherence.

5. What legal strategies are employed to extend patent protections?
   Patent term extensions, secondary patents covering formulations or methods of use, and strategic filing of global patents are common tactics to extend market exclusivity.

---

Key Takeaways

• The PTH analog market is set for growth owing to clinical efficacy and expanding indications but is heavily influenced by patent expirations.
• Patent landscapes are complex, with core molecule patents expiring around 2027, paving the way for biosimilar competition.
• Biosimilar development is robust, with multiple candidates aiming for approval, potentially disrupting market pricing and access.
• Innovation in formulations, delivery methods, and indications constitutes a significant opportunity to extend market relevance.
• Regulatory and legal hurdles, including patent litigation and approval timelines, remain key determinants of market entry and timeline.

---

References

1. [1] IQVIA Institute for Human Data Science. (2022). "The Future of Biosimilars in the US."
2. [2] FDA. (2022). "Guidance for Industry: Biosimilar Product Development."
3. [3] European Medicines Agency. (2022). "Biosimilar Medicines."
4. [4] Eli Lilly and Company. (2022). Patent filings and legal updates.
5. [5] MarketWatch. (2023). "Global PTH Drug Market Forecasts."